CClinicalTrials.gg
CompletedNCT02536040Updated Jan 23, 2020Results posted

Stopping Cavities Study: Diammine Silver Fluoride

A Phase 3 interventional study of 38% diammine silver fluoride and Water in Dental Caries, sponsored by Advantage Dental Services, LLC. Completed at 1 site in United States. Open to participants aged 24 Months to 60 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-23.

Sponsored by Advantage Dental Services, LLC · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
24 Months to 60 Months
Sex
All
01

Study summary

This study is being conducted to test whether the use of diammine silver fluoride (also called silver diamine fluoride) hardens the cavity sufficiently so that it arrests.

Read the detailed description

Phase III RCT with two arms: (1) 38% diammine silver fluoride; (2) distilled fluoride free water. Subjects are 200 preschool children in good general health with untreated tooth decay. Intervention is topical application of the study drug to the open cavity. Primary outcome is caries activity at 14-21 days.

02

Conditions studied

  • Dental Caries

Browse trials for

Keywords

  • silver diamine fluoride
  • diammine silver fluoride
  • children
03

In context

Dental Caries

1,107 studies on the registry are indexed under Dental Caries; 197 are open to participants now.

This study's enrollment of 66 is close to the median of 60 across 915 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

Advantage Dental Services, LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Nyvad criteria 3
  • Active carious lesion

Exclusion criteria

Exclusion Criteria:

  • Allergy to silver
  • Stomatitis or oral ulcerative condition
  • Weight less than 15 kg
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    38% diamine silver fluoride

    Topical application of 38% diammine silver fluoride to active cavity

    Drug: 38% diammine silver fluoride

  • Placebo comparator
    Water

    Topical application of fluoride free water to active cavity

    Other: Water

Interventions

  • Drug38% diammine silver fluoride

    treatment of cavity with study agent

    Also known as: silver fluoride, silver diamine fluoride

  • OtherWater

    Fluoride free, distilled water

06

What researchers measure

Primary outcomes

  1. Dental Caries Activity

    Proportion of treated teeth with active decay that were arrested by the treatment measured using the Nyvad criterion code 6 reflecting hardness of the lesion and color change

    Time frame: 14-21 days

07

Results

Posted Jan 23, 2020

Participant flow

Participant flow — Overall Study
Milestone38% Diamine Silver FluorideWater
Started3036
Completed2935
Not completed11

Outcome measures

PrimaryDental Caries Activity

Proportion of treated teeth with active decay that were arrested by the treatment measured using the Nyvad criterion code 6 reflecting hardness of the lesion and color change

Time frame:
14-21 days
Reported as:
Mean · Proportion of arrested caries lesions
Dental Caries Activity
Proportion of arrested caries lesions38% Diamine Silver FluorideWater
Dental Caries Activity.72 ± .38.05 ± .18

Adverse events

Collected over The primary focus of the adverse events clinical examination was to detect intramural soft tissue changes 2 days following the localized treatment of the teeth. It was not measured 14-21 days later when the primary outcome was assessed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
38% Diamine Silver Fluoride0/29 (0%)0/29 (0%)0/29 (0%)
Water0/35 (0%)0/35 (0%)0/35 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)38% Diamine Silver FluorideWaterTotal
Mean4.7 ± .64.9 ± .54.8 ± .6
Sex: Female, Male
Sex: Female, Male(Participants)38% Diamine Silver FluorideWaterTotal
Female131831
Male161733
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)38% Diamine Silver FluorideWaterTotal
Hispanic or Latino152338
Not Hispanic or Latino141226
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)38% Diamine Silver FluorideWaterTotal
American Indian or Alaska Native202
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White273360
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)38% Diamine Silver FluorideWaterTotal
United States293564
08

Study locations

1 site
  • Advantage Dental Plans
    Redmond, Oregon 97756, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02536040
Lead sponsor
Advantage Dental Services, LLC
Responsible party
Sponsor
First posted
Aug 31, 2015
Start date
Jan 2016
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Jan 23, 2020
Last update
Jan 23, 2020

Study contacts

Peter Milgrom, DDS
study director · Advantage Dental Plans

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion